IL13 and neoplasm: However, in advanced tumors, anti-inflammatory mediators released in the TME, such as CSF-1, CCL2, IL13, IL4, IL10, and prostaglandin E2 (PGE2), can revert the anti-tumor program and favor a switch of TAM into an M2 phenotype with pro-tumor and immunosuppressive functions [131,132].